Rhinovirus 16 2A Protease Affects Nuclear Localization of 3CD during Infection.
The human rhinovirus (HRV) 3C and 2A proteases (3Cproand 2Apro, respectively) are critical in HRV infection, as they are required for viral polyprotein processing as well as proteolysing key host factors to facilitate virus replication. Early in infection, 3Cprois present as its precursor 3CD, which, although the mechanism of subcellular targeting is unknown, is found in the nucleus as well as the cytoplasm. In this study, we use transfected and infected cell systems to show that 2Aproactivity is required for 3CD nuclear localization. Using green fluorescent protein (GFP)-tagged forms of 3Cpro, 3D, and mutant derivatives thereof, we show that 3Cprois located in the cytoplasm and the nucleus, whereas 3CD and 3D are localized predominantly in the cytoplasm, implying that 3D lacks nuclear targeting ability and that 3Cproactivity within 3CD is not sufficient to allow the larger protein into the nucleus. Importantly, by coexpressing mCherry-2Aprofusion proteins, we demonstrate formally that 2Aproactivity is required to allow HRV 3CD access to the nucleus. In contrast, mCherry-3Cprois insufficient to allow 3CD access to the nucleus. Finally, we confirm the relevance of these results to HRV infection by demonstrating that nuclear localization of 3CD correlates with 2Aproactivity and not 3Cproactivity, which is observed only later in infection. The results thus define the temporal activities of 2Aproand 3CD/3Cproactivities in HRV serotype16 infection.


OBJECTIVE
The human rhinovirus genome encodes two proteases, 2A and 3C, as well as a precursor protease, 3CD. These proteases are essential for efficient virus replication. The 3CD protein is found in the nucleus early during infection, though the mechanism of subcellular localization is unknown. Here we show that 2A protease is required for this localization, the 3C protease activity of 3CD is not sufficient to allow 3CD entry into the nucleus, and 3D lacks nuclear targeting ability. This study demonstrates that both 2A and 3C proteases are required for the correct localization of proteins during infection and defines the temporal regulation of 2A and 3CD/3C protease activities during HRV16 infection.
Centre for Research in Therapeutic Solutions, University of Canberra, Canberra, Australian Capital Territory, Australia.
Erin
E
Walker
Centre for Research in Therapeutic Solutions, University of Canberra, Canberra, Australian Capital Territory, Australia.
Lora
L
Jensen
Centre for Research in Therapeutic Solutions, University of Canberra, Canberra, Australian Capital Territory, Australia.
Sarah
S
Croft
Centre for Research in Therapeutic Solutions, University of Canberra, Canberra, Australian Capital Territory, Australia.
Kejun
K
Wei
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.|Monash Micro Imaging, Monash University, Clayton, Victoria, Australia.
Alex J
AJ
Fulcher
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
David A
DA
Jans
Centre for Research in Therapeutic Solutions, University of Canberra, Canberra, Australian Capital Territory, Australia Reena.Ghildyal@canberra.edu.au.
Reena
R
Ghildyal
D000086042:3C Viral Proteases; D002467:Cell Nucleus / Q000821:virology; D003546:Cysteine Endopeptidases / Q000235:genetics* / Q000378:metabolism; D003593:Cytoplasm / Q000821:virology*; D015967:Gene Expression Regulation, Viral; D017930:Genes, Reporter; D049452:Green Fluorescent Proteins / Q000235:genetics / Q000378:metabolism; D006367:HeLa Cells; D054884:Host-Pathogen Interactions; D006801:Humans; D008164:Luminescent Proteins / Q000235:genetics / Q000378:metabolism; D021381:Protein Transport; D059748:Proteolysis; D012229:Rhinovirus / Q000145:classification / Q000235:genetics* / Q000378:metabolism; D065288:Serogroup; D014764:Viral Proteins / Q000235:genetics* / Q000378:metabolism; D014779:Virus Replication; D000097573:Red Fluorescent Protein
D000086042:3C Viral Proteases; D003546:Cysteine Endopeptidases; D049452:Green Fluorescent Proteins; D008164:Luminescent Proteins; D014764:Viral Proteins; D000097573:Red Fluorescent Protein; C057400:picornain 2A, Picornavirus
Methods Mol Biol. 2015;1221:129-41
25261311
Acta Biochim Biophys Sin (Shanghai). 2011 Jan;43(1):38-44
21173057
PLoS One. 2013 Aug 07;8(8):e71316
23951130
J Virol. 2008 Oct;82(19):9389-99
18632855
J Virol. 1999 Jan;73(1):718-27
9847378
Virology. 2006 Jun 5;349(2):409-21
16624365
PLoS Pathog. 2014 Jun 26;10(6):e1004199
24968230
Traffic. 2005 Mar;6(3):173-86
15702986
Virology. 2013 Sep;444(1-2):203-10
23886493
J Virol. 2003 Apr;77(8):5026-9
12663812
Cancer Res. 2005 Aug 15;65(16):7059-64
16103052
Future Virol. 2012 Feb;7(2):179-191
23293659
J Virol. 2011 Oct;85(20):10874-83
21835805
J Virol. 2002 Mar;76(5):2062-74
11836384
J Virol. 2010 Aug;84(15):7418-26
20375160
Front Microbiol. 2015 Aug 24;6:875
26379650
J Virol. 2003 Jun;77(11):6235-44
12743280
J Virol. 2009 Jul;83(14):7349-52
19403669
J Virol. 2002 Sep;76(17 ):8787-96
12163599
J Exp Med. 2005 Mar 21;201(6):937-47
15781584
Mol Cell Biol. 2004 Feb;24(4):1779-90
14749392
Biochemistry. 2005 Sep 27;44(38):12887-95
16171404
Methods Mol Biol. 2015;1221:171-80
25261314
J Biol Chem. 2010 Sep 10;285(37):28796-805
20622012
J Med Virol. 2005 Apr;75(4):608-15
15714497
Bioessays. 2000 Jun;22(6):532-44
10842307
Virol J. 2014 Nov 20;11:192
25410318
Viruses. 2015 Nov 25;7(12):6127-40
26610553
Arch Biochem Biophys. 1997 Oct 1;346(1):125-30
9328292
Biophys J. 2009 Sep 2;97(5):1288-94
19720016
J Biol Chem. 1993 Sep 15;268(26):19200-3
8396129
Virus Res. 2003 Sep;95(1-2):75-85
12921997
Virology. 2004 Mar 15;320(2):195-205
15016543
J Biol Chem. 1991 Aug 5;266(22):14714-20
1713590
Cell. 2003 Feb 21;112(4):441-51
12600309
J Gen Virol. 2004 Oct;85(Pt 10):2969-79
15448360